Dana-Farber Cancer Institute to Study Paxalisib in Lymphoma-based Brain Cancer
Boston-based Dana-Farber Cancer Institute (DFCI) entered into a collaborative agreement with an Australian oncology-focused biotech called Kazia Therapeutics Limited (ASX: […]